Home › Heart Failure › NCT06593314

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

Identifying Undiagnosed HFpEF Among Patients With Type 2 Diabetes Using Ultromics AI HFpEF Algorithm

Who can join

All ages · All sexes

Clinical cohort inclusion exclusion criteria:

Inclusion Criteria:

* Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
* Echocardiogram available in last 6-months.

Exclusion Criteria:

* History of HF
* Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA

Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.

About the study

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

What is being tested

• Message with EchoGo (behavioral)
• Standard Message (behavioral)

Sponsor: University of Texas Southwestern Medical Center · Participants: 800 · Started: Aug 6, 2025

Contact the study team

• Ambarish Pandey, MD · Phone: 617-869-8957

Official record on ClinicalTrials.gov — NCT06593314

Locations in the U.S.

Conditions

• Heart Failure
• Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.